GlassScriptPhysician profile
Damian Portela
NPI 1194703330
$3,473.14
in general payments reported to CMS, 2019-2025
34 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $72.32 · 2021: $360 · 2022: $345 · 2023: $536 · 2024: $1,096 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Education: $363 · Travel and Lodging: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.73 |
| Education | $363.39 |
| Travel and Lodging | $258.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $618.50 | 2019-2025 | Xtandi |
| Procept Biorobotics Corporation | $488.93 | 2024 | Aquabeam System |
| Endo Pharmaceuticals INC. | $382.63 | 2020-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $260.84 | 2024-2025 | Xiaflex, Aveed, Edex |
| Boston Scientific Corporation | $238.31 | 2019-2025 | Lumenis Pulse 120h, Lithovue, Ams 700 |
| Pfizer INC. | $236.38 | 2019-2025 | |
| Janssen Biotech, INC. | $223.05 | 2019-2025 | Erleada |
| Coloplast Corp | $127.88 | 2019-2025 | Speedicath |
| Neotract INC. | $83.54 | 2019 | |
| Sumitomo Pharma America, INC. | $81.72 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $77.90 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $59.18 | 2024 | Tlando |
| Dentsply Ih INC. | $58.54 | 2019-2020 | |
| Axonics, INC. | $48.85 | 2022-2024 | Axonics |
| Urovant Sciences INC | $43.59 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $43.02 | 2023-2024 | Endosheath Technology |
| Novartis Pharmaceuticals Corporation | $41.62 | 2022-2023 | |
| Caldera Medical, INC | $37.96 | 2021 | |
| Conmed Corporation | $29.98 | 2024 | Airseal |
| Antares Pharma, INC. | $28.54 | 2019 | |
| Foundation Medicine, INC. | $27.66 | 2022 | |
| Caris Mpi, INC. | $26.03 | 2025 | Mi Cancer Seek |
| Agiliti Surgical, INC. | $25.22 | 2025 | Koelis Trinity Mri/US Fusion, Boston Scientific Lumenis Pulse 120h Holmium Laser W/ Moses Technology |
| Kowa Pharmaceuticals America, INC. | $20.57 | 2022 | |
| Olympus America INC. | $19.38 | 2025 | Itind System |
| Therapeuticsmd, INC. | $19.21 | 2019 | |
| Calyxo, INC. | $19.08 | 2025 | Cvac Aspiration System |
| C. R. Bard, INC. & Subsidiaries | $18.76 | 2022 | |
| Valencia Technologies Corporation | $16.83 | 2025 | Ecoin Device Kit |
| Photocure INC | $15.85 | 2024 | Cysview |
| Abbvie INC. | $14.16 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $14.12 | 2021 | |
| Medtronic USA, INC. | $13.85 | 2019 | |
| Mission Pharmacal Company | $11.46 | 2024 | Uribel Tabs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damian Portela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.